Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 6/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.60 |
| ▸ | MAPT | P10636 | 5/20 | 0.60 |
| ▸ | POLB | P06746 | 4/20 | 0.60 |
| ▸ | HPGD | P15428 | 4/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | RECQL | P46063 | 4/20 | 0.60 |
| ▸ | BLM | P54132 | 4/20 | 0.60 |
| ▸ | PMP22 | Q01453 | 4/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.60 |
| ▸ | USP2 | O75604 | 3/20 | 0.60 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.60 |
| ▸ | APEX1 | P27695 | 3/20 | 0.60 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.60 |
| ▸ | MTOR | P42345 | 3/20 | 0.60 |
| ▸ | EGFR | P00533 | 2/20 | 0.60 |
| ▸ | FYN | P06241 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11574844 | 1.00 | KDM4E (0.60) | KDM4EHSD17B10ALOX15TDP1MAPT | |
| SCHEMBL11081595 | 0.82 | BLM (0.57) | KDM4EHSD17B10ALOX15TDP1MAPT | |
| SCHEMBL11078710 | 0.82 | BLM (0.57) | KDM4EHSD17B10ALOX15TDP1MAPT | |
| SCHEMBL11084247 | 0.80 | GRM2 (0.44) | KDM4EALOX15MAPTALDH1A1BLM | |
| SCHEMBL1274883 | 0.78 | SMN1; SMN2 (0.58) | KDM4EMAPTBLMPMP22LMNA | |
| SCHEMBL1274884 | 0.78 | SMN1; SMN2 (0.58) | KDM4EMAPTBLMPMP22LMNA | |
| SCHEMBL19636683 | 0.78 | KDM4E (0.60) | KDM4EHSD17B10ALOX15TDP1MAPT | |
| SCHEMBL16091667 | 0.78 | KDM4E (0.60) | KDM4EHSD17B10ALOX15TDP1MAPT | |
| Benserazide SCHEMBL23797826 | 0.77 | KDM4E (0.63) | KDM4EHSD17B10ALOX15TDP1MAPT | |
| SCHEMBL10780736 | 0.76 | KDM4E (0.62) | KDM4EHSD17B10ALOX15TDP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 225 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12048764-B2 | Levodopa infusion solution | DIZLIN PHARMACEUTICALS AB (SE) | 2024-07-30 | — | — | US | claimed |
| EP-3638673-B1 | TETRAHYDROPYRIDOPYRAZINE MODULATORS OF GPR6 | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-17 | — | — | EP | claimed |
| EP-3856196-B1 | PHENYLPROPIONIC ACID DERIVATIVES FOR MODULATING PATHOGEN ACTIVITY | UNIV GRIFFITH (AU) | 2023-11-15 | — | — | EP | claimed |
| US-20230330015-A1 | LEVODOPA INFUSION SOLUTION | DIZLIN PHARMACEUTICALS AB (SE) | 2023-10-19 | — | — | US | claimed |
| CN-110730781-B | Tetrahydropyridopyrazine modulators of GPR6 | 武田药品工业株式会社 | 2023-05-05 | — | — | CN | claimed |
| US-11633353-B2 | Levodopa infusion solution | DIZLIN PHARMACEUTICALS AB (SE) | 2023-04-25 | — | — | US | claimed |
| US-20230078925-A1 | PULSATILE DRUG DELIVERY SYSTEM FOR TREATING MORNING AKINESIA | CONTERA PHARMA AS (DK) | 2023-03-16 | — | — | US | claimed |
| US-11547689-B2 | Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders | INTRANCE INTERNATIONAL AB (SE) | 2023-01-10 | — | — | US | claimed |
| US-20210378954-A9 | LEVODOPA INFUSION SOLUTION | DIZLIN PHARMACEUTICALS AB (SE) | 2021-12-09 | — | — | US | claimed |
| US-20210338685-A1 | AGENTS AND METHODS FOR MODULATING PATHOGEN ACTIVITY | RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL | 2021-11-04 | — | — | US | claimed |
| CN-105473545-A | Dihydroxyphenyl neurotransmitter compounds, compositions, and methods | AUSPEX PHARMACEUTICALS INC | 2016-04-06 | — | — | CN | claimed |
| WO-2015095257-A2 | MANAGING VISUAL DYSFUNCTION OR LOSS OF VISION FOR DIABETIC SUBJECTS | EMORY UNIVERSITY (US) | 2015-06-25 | — | — | WO | claimed |
| WO-2015006315-A1 | DIHYDROXYPHENYL NEUROTRANSMITTER COMPOUNDS, COMPOSITIONS AND METHODS | AUSPEX PHARMACEUTICALS, INC. (US) | 2015-01-15 | — | — | WO | claimed |
| US-20040101523-A1 | Renal-selective prodrugs for control of renal smpathetic nerve activity in the treatment of hypertension | G.D. SEARLE & CO. | 2004-05-27 | — | — | US | claimed |
| US-20030220521-A1 | Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension | G.D. SEARLE & CO. | 2003-11-27 | — | — | US | claimed |
| EP-0484437-A4 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | SEARLE & CO (US) | 1994-06-01 | — | — | EP | claimed |
| EP-0484437-A1 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | G.D. Searle & Co. (US) | 1992-05-13 | — | — | EP | claimed |
| WO-1992001667-A1 | RENAL-SELECTIVE PRODRUGS FOR CONTROL OF RENAL SYMPATHETIC NERVE ACTIVITY IN THE TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1992-02-06 | — | — | WO | claimed |
| WO-1991001724-A1 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1991-02-21 | — | — | WO | claimed |
| US-4413012-A | Method for treating depression | MERRELL TORAUDE ET COMPAGNIE (FR) | 1983-11-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220521-A1 | Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension | GLS, APEH, GGH | KDM4E 1203/4885HSD17B10 268/4885ALOX15 1960/4885 |
| US-11547689-B2 | Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders | COMT, DBH, PARK7 | KDM4E 3090/4885HSD17B10 675/4885ALOX15 1061/4885 |
| US-20210338685-A1 | AGENTS AND METHODS FOR MODULATING PATHOGEN ACTIVITY | C3AR1, HAVCR2, C5AR1 | KDM4E 4806/4885HSD17B10 4517/4885ALOX15 1696/4885 |
| US-20040101523-A1 | Renal-selective prodrugs for control of renal smpathetic nerve activity in the treatment of hypertension | GLS, DBH, APEH | KDM4E 935/4885HSD17B10 392/4885ALOX15 1824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.